Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
  • Patient Engagement
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
Advance your patient engagement strategy

Discover new patient engagement possibilities with IQVIA insights, expertise, and technology-driven solutions.

Patient Engagement Overview
Patient Engagement Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2024

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience powered by Apple
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions powered by Apple

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Blog
An update on treatment options and pipeline developments for Duchenne muscular dystrophy
IQVIA Pipeline Intelligence
Sam Lam, Senior Analyst, IQVIA Pipeline Intelligence
Apr 06, 2021

Duchenne muscular dystrophy (DMD) is a rare X-linked progressive genetic disorder and the most common and severe type of dystrophinopathy. It is characterized by mutations in the DMD gene that prevent the production of functional dystrophin, a structural protein involved in maintaining the integrity of muscle cells. The absence of dystrophin in muscles leads to muscle degeneration, loss of ambulation and cardiomyopathy. According to statistics from the National Organization for Rare Disorders (USA), DMD occurs in approximately one out of every 3,500 male infants worldwide. The current therapies alleviate the symptoms and have been shown to slow the progression of the disease. Newer exon skipping therapies can halt the progression of DMD but only work in a subset of DMD patients with certain gene mutations and do not cure the disease. The first phase III DMD gene therapy program commenced patient enrollment in January 2021 and following this milestone, a gene therapy to deliver a healthy copy of the dystrophin gene may provide a cure for this debilitating disease. This article will provide an update on current treatment options for DMD and outline the latest development activities of key experimental drugs with data sourced from IQVIA Pipeline Intelligence, a proprietary drug pipeline database.

CURRENT TREATMENT OPTIONS FOR DMD:

Corticosteroids

Corticosteroids, including prednisone and deflazacort, have been commonly used to treat DMD. Corticosteroids act by delaying the progression of muscle weakness and reducing inflammation by inhibiting the expression of pro-inflammatory genes. While the first corticosteroid won US FDA approval for the treatment of DMD in 2017, the widely available generic prednisone is frequently prescribed for the disease but does not have formal US FDA approval.

Antisense-mediated exon skipping therapies

Gene-targeted treatments have also been investigated for DMD, including exon skipping therapies which mask specific exons in a gene sequence of the DMD gene and gene therapies to deliver a healthy DMD gene directly to a patient. There are currently four antisense-mediated exon skipping therapies approved by the US FDA for DMD.

KEY SELECTED NEXT-GENERATION THERAPEUTICS FOR DMD:

Gene therapies

Recent progress has been made in the development of gene therapies to cover all patients regardless of mutation. Despite the identification of the dystrophin gene in 1986, which is the largest human gene (2,200 kb in size), it has proved a challenge to transfer the gene into adeno-associated viruses (AAV) used to deliver gene therapies due to its size. As the carrying capacity of AAVs is approximately 4.7 kb, instead of utilizing the full dystrophin gene, researchers engineered smaller, modified genes that produce a shortened form of dystrophin: micro-dystrophin (gene size 3.5 to 4 kb) and mini-dystrophin (gene size 6 to 8 kb) that are designed to function like the normal dystrophin protein. There are currently several key gene therapies in clinical development for DMD.

GENOME-EDITING THERAPIES

With the development of genome editing systems, including CRISPR/Cas9 it is now possible to make targeted modifications in the genome. Gene-editing therapies can restore the expression of partially functional dystrophin protein by reframing DMD mutations at the genomic level and potentially provide a cure for the disease. Although no CRISPR-based therapies have entered clinical development yet, several companies are working on CRISPR programs for DMD.

FUTURE DIRECTIONS

Many advances have been made over the last few decades in elucidating the molecular mechanisms of DMD since the discovery of the dystrophin gene, which has aided the emergence of new gene-based therapies. This has opened the door for combination therapies, with the use of gene therapies to stabilize muscle and small molecule drugs such as anti-inflammatory therapies to combat the downstream effects of fibrosis and inflammation. The latest developments could provide DMD patients further treatment options and potentially increased benefit.

Contact Us